Topical Sirolimus for the Treatment of Pachyonychia Congenita (PC)
Phase 1
Completed
- Conditions
- Pachyonychia Congenita
- Interventions
- Drug: 1% sirolimus cream (TD201 1%)
- First Posted Date
- 2014-06-02
- Last Posted Date
- 2016-10-07
- Lead Sponsor
- TransDerm, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT02152007
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
© Copyright 2025. All Rights Reserved by MedPath